{"entity":{"id":"starna-therapeutics","kind":"company","name":"Starna Therapeutics","aka":["星锐医药"],"tldr":"Starna Therapeutics develops RNA medicines carried in fat particles designed to reach tissues outside the liver. Its STR-P004 aims to turn a patient's own immune cells into CAR-T cells inside the body, and is in an early study in B-cell non-Hodgkin lymphoma.","summary":"Starna Therapeutics (Suzhou) Co., Ltd. develops RNA-based medicines on a lipid nanoparticle platform for extrahepatic delivery, with tissue-specific and cell-selective nanoparticles. STR-P004 is an intravenously given in vivo CAR-T drug; the company describes it for autoimmune disease, and the early clinical study NCT07003178 at a single centre in Suzhou tests it in relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma. Its other disclosed programme is STR-V003, a respiratory syncytial virus vaccine. The company reported a Series B of more than 300 million yuan in October 2025, co-led by LYFE Capital, Hillhouse and Lilly Asia Ventures, and a Series B+ of nearly 40 million US dollars in May 2026. Its first registered cancer trial, NCT07003178, was posted on ClinicalTrials.gov in June 2025; its first registry study overall, posted in April 2024, was an RSV vaccine trial.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.starnatx.com/"},{"label":"ClinicalTrials.gov: early study of STR-P004 in B-cell non-Hodgkin lymphoma (NCT07003178)","url":"https://clinicaltrials.gov/study/NCT07003178"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","The funding rows are from headlines and summaries on the company home page; the individual news pages were not read in full.","Company website read on 29 October 2026."],"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.starnatx.com/","stage":"growth","investors":[],"funding":[{"round":"Series B","year":2025,"source":"https://www.starnatx.com/news/22","note":"More than 300 million yuan, co-led by LYFE Capital, Hillhouse and Lilly Asia Ventures, as summarised on the company website. No US dollar figure stated."},{"round":"Series B+","year":2026,"source":"https://www.starnatx.com/news/53","note":"Nearly 40 million US dollars (近4000万美元) per the company headline, with Hillhouse, LYFE Capital, Lilly Asia Ventures and Chunhwa Ventures among investors; amountUsd omitted because the figure is approximate."}]},"route":"/companies/starna-therapeutics/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}]}}